Oncology

The cofounder and chief scientific officer of Xcell Biosciences discussed the company’s research with a newly developed assay method that was presented at AACR’s 2023 conference.

Review top news and interview highlights from the week ending May 5, 2023.

The head of immunology at Turn Biotechnologies discussed preclinical data demonstrating proof-of-concept with the company’s epigenome reprogramming platform.

The decision, which aligns with its indication in the US, was based on efficacy and safety results from Bristol Myers Squibb’s TRANSFORM clinical trial in forms of large B-cell lymphoma.

The cofounder and chief executive officer of NKILT Therapeutics discussed new preclinical data presented at WOCTC.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Bristol Myers Squibb noted that in addition to meeting the ORR end point, both trials also met a key secondary CR rate end point.

The chief medical officer of Trisalus Life Sciences discussed the company’s PEDD system and SD-101.

Kiromic BioPharma expects to initiate a phase 1 clinical trial for Deltacel within Q2 2023.

The cofounder and chief scientific officer of Xcell Biosciences discussed the limitations of the methods currently used for modeling in preclinical cell therapy research for solid tumors.

The senior director of immunology at Arsenal Bio discussed advantages of ICTs and the company’s clinical trial in ovarian cancer.

The vice president of business development and alliances at Prescient Therapeutics discussed the mechanism of the OmniCAR technology.

Review top news and interview highlights from the week ending April 28, 2023.

The scientific cofounder and chief executive officer of Alloplex Biotherapeutics discussed early data from a phase 1 trial of the PBMC-derived therapy.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The associate director of research at Lyell Immunopharma discussed the company’s programs and newest technologies aimed at solid tumors.

The instructor at Stanford Institutes of Medicine discussed the key takeaways of her research into the factors that affect CAR-T expansion.

The research scientist at Moffitt Cancer Center discussed the results of the preclinical study she presented at the 2023 AACR annual meeting and avenues for further research.

The professor of breast cancer research at Indiana University discussed new research with the TONSL gene from Indiana University.

Review top news and interview highlights from the week ending April 21, 2023.

Overall, 6 patients were treated in a feasibility study for a disease control rate of 33.3%.

The research scientist at Moffitt Cancer Center shared the rationale behind the preclinical study she presented at the 2023 AACR annual meeting.

The pediatric clinical pharmacist in stem cell transplant and cellular therapy at the University of Minnesota Masonic Children’s Hospital and M Health Fairview offered an in-depth preview of the upcoming virtual meeting.

The investigators created the largest known CAR-T atlas, with more than 800,000 cells in total, providing a new exploration into the phenotyping of T-cells.

Investigators have initiated the BASECAMP-1 trial of investigational agent A2B530 with the hope of identifying patients with advanced solid tumors who will be suitable candidates for treatment in a subsequent trial.

The investigators from Children’s Hospital of Philadelphia discussed the follow-up studies they are conducting in light of their recent findings regarding DNA virus replication.

Vax-CAR-T cells significantly suppressed tumor growth in mouse models in both smaller and larger tumors.

The assistant professor of stem cell transplantation at MD Anderson Cancer Center discussed updated data on ALLO-316 in patients with ccRCC.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The CAR-T therapy reduced disease progression risk by 74%, according to a data leak reported by STAT News. The data are expected to be presented on May 11 at the 2023 European Hematology Association Congress.